The Doctors Company and ProAssurance
On March 19, 2025, ProAssurance (‘PRA’) announced they agreed to be acquired by The Doctors Company (‘TDC’) for $1.3 billion in cash. The transaction is not subject to a financing condition but to the approval by PRA’s stockholders and the receipt of regulatory approvals.
Time will tell us if this deal is actually a game changer for the MPL industry.
Here is what I have been thinking:
1- PRA is a public company. There can be another suitor. Who?
- Berkshire Hathaway/MedPro? They would have an even harder time with anti-trust regulators.
- Coverys? Technically possible with their surplus of $1.4 billion.
- A private equity fund? They hate to do hostile mid-cap deals but this is possible.
The stockholders won't push back with that stock price bump at $25 per share, a 60% premium compared to market price.
PRA has been available for the past 4-5 years. Their acquisition of NORCAL was intended to make them more attractive for a buyer. If someone else were seriously interested, Goldman Sachs (financial advisor to PRA) would already know. We'll see soon.
2- Anti-trust reaction
The acquisition may be under scrutiny from regulators in several states, where the combined concern is close to anti-trust thresholds: California, Nevada, Florida, Michigan, ...
The new giant may even need to sell parts of their books: an opportunity for others?
But the MPL market is notoriously fragmented nationwide with top 20 carriers accounting for only 60% market share. So, this deal should go through.
3- Integration
As for most larger M&A transactions, Integration will be the main challenge indeed, and it will be very long.
TDC has a strong track record of acquisitions integration, but PRA is not just another acquisition.
They can expect higher turnover with management and higher churn with policy holders: yet another opportunity for MPL insurance carriers.
4- Consequences on MPL market and competition
This major deal will trigger another round of consolidation.
Larger carriers with deeper pockets ($12 billion combined surplus for TDC/PRA) will only tease plaintiff bars and juries towards more mega verdicts.
It may also lead to firmer premiums, which is not bad for the market.
Eventually, the independent players will have an even more pressing need to enhance operational efficiency.
What other thoughts do you want to share?